CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC

CME-certified Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach

Gerard A. Silvestri, MD, MS
Program Director Kristin Higgins, MD Mark A. Socinski, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: November 20, 2019 Expiration: November 19, 2020

In this slideset, experts provide insights on immunotherapy use for stage III NSCLC today and emerging developments in this setting and earlier stages of NSCLC.

Roy S. Herbst, MD, PhD Melissa L. Johnson, MD Released: November 8, 2019

In this slideset, Sanjay Mukhopadhyay, MD, reviews biomarker testing in lung cancer, including molecular testing by NGS and PD-L1 testing to predict response to checkpoint inhibitors.

Sanjay Mukhopadhyay, MD Released: November 5, 2019

In this slideset, Joshua Bauml, MD; Sandip P. Patel, MD; and H. Jack West, MD, review the latest clinical data supporting the optimal use of biomarker testing for checkpoint inhibitor therapy across lung cancer.

H. Jack West, MD
Program Director Joshua Bauml, MD Sandip P. Patel, MD Released: November 5, 2019